Neil Desai, PhD, is the Founder and CEO of Aanastra, Inc., a company that is pioneering novel peptide-based RNA therapeutic drug delivery for cancer and genetic diseases. Dr. Desai is also the founder, Executive Chairman and former CEO (2014-Dec 2022) of Aadi Bioscience (AADI: Nasdaq), which he steered to the public market in Aug 2021, and to the approval and commercialization of its drug FYARRO, the first FDA approved therapy for advanced PEComa. He built Aadi from a single person to over 80 employees and raised multiple financing rounds (private and public). He is the inventor of the nab-sirolimus (FYARRO) and nab-paclitaxel (ABRAXANE). He was previously the SVP of global R&D at Abraxis Bioscience, where he grew and led the Abraxane team from early discovery through approvals in Breast, Lung and Pancreatic cancer. Abraxis was acquired by Celgene Corp for ~ $3B in 2010. Dr Desai was subsequently VP of Strategic Platforms at Celgene until 2016. Dr. Desai has over 100 issued patents and over 40 peer-reviewed publications. He received a M.S and Ph.D. in Chemical Engineering from the University of Texas at Austin, and a B.S. in Chemical Engineering from the University Institute of Chemical Technology in Mumbai, India.